Triple-negative breast cancer: Current understanding and future therapeutic breakthrough targeting cancer stemness

Kha Liang Lee, Yung Che Kuo, Yuan Soon Ho, Yen Hua Huang

研究成果: 雜誌貢獻回顧型文獻

6 引文 (Scopus)

摘要

Triple-negative breast cancer (TNBC) is cancer that tested as negative for estrogen receptors (ER), progesterone receptors (PR), and excess human epidermal growth factor receptor 2 (HER2) protein which accounts for 15%-20% of all breast cancer cases. TNBC is considered to be a poorer prognosis than other types of breast cancer, mainly because it involves more aggressive phenotypes that are similar to stem cell-like cancer cells (cancer stem cell, CSC). Thus, targeted treatment of TNBC remains a major challenge in clinical practice. This review article surveys the latest evidence concerning the role of genomic alteration in current TNBC treatment responses, current clinical trials and potential targeting sites, CSC and drug resistance, and potential strategies targeting CSCs in TNBC. Furthermore, the role of insulin-like growth factor 1 receptor (IGF-1R) and nicotinic acetylcholine receptors (nAChR) in stemness expression, chemoresistance, and metastasis in TNBC and their relevance to potential treatments are also discussed and highlighted.

原文英語
文章編號1334
期刊Cancers
11
發行號9
DOIs
出版狀態已發佈 - 九月 2019

指紋

Triple Negative Breast Neoplasms
Neoplastic Stem Cells
Neoplasms
Therapeutics
Breast Neoplasms
Somatomedin Receptors
Nicotinic Receptors
Progesterone Receptors
Drug Resistance
Estrogen Receptors
Clinical Trials
Neoplasm Metastasis
Phenotype

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

引用此文

Triple-negative breast cancer : Current understanding and future therapeutic breakthrough targeting cancer stemness. / Lee, Kha Liang; Kuo, Yung Che; Ho, Yuan Soon; Huang, Yen Hua.

於: Cancers, 卷 11, 編號 9, 1334, 09.2019.

研究成果: 雜誌貢獻回顧型文獻

@article{025cd45f851f463c8bd887fe39d6917d,
title = "Triple-negative breast cancer: Current understanding and future therapeutic breakthrough targeting cancer stemness",
abstract = "Triple-negative breast cancer (TNBC) is cancer that tested as negative for estrogen receptors (ER), progesterone receptors (PR), and excess human epidermal growth factor receptor 2 (HER2) protein which accounts for 15{\%}-20{\%} of all breast cancer cases. TNBC is considered to be a poorer prognosis than other types of breast cancer, mainly because it involves more aggressive phenotypes that are similar to stem cell-like cancer cells (cancer stem cell, CSC). Thus, targeted treatment of TNBC remains a major challenge in clinical practice. This review article surveys the latest evidence concerning the role of genomic alteration in current TNBC treatment responses, current clinical trials and potential targeting sites, CSC and drug resistance, and potential strategies targeting CSCs in TNBC. Furthermore, the role of insulin-like growth factor 1 receptor (IGF-1R) and nicotinic acetylcholine receptors (nAChR) in stemness expression, chemoresistance, and metastasis in TNBC and their relevance to potential treatments are also discussed and highlighted.",
keywords = "Cancer stem cell, IGF-1R, NACHR, Recurrence, Resistance, TNBC",
author = "Lee, {Kha Liang} and Kuo, {Yung Che} and Ho, {Yuan Soon} and Huang, {Yen Hua}",
year = "2019",
month = "9",
doi = "10.3390/cancers11091334",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",

}

TY - JOUR

T1 - Triple-negative breast cancer

T2 - Current understanding and future therapeutic breakthrough targeting cancer stemness

AU - Lee, Kha Liang

AU - Kuo, Yung Che

AU - Ho, Yuan Soon

AU - Huang, Yen Hua

PY - 2019/9

Y1 - 2019/9

N2 - Triple-negative breast cancer (TNBC) is cancer that tested as negative for estrogen receptors (ER), progesterone receptors (PR), and excess human epidermal growth factor receptor 2 (HER2) protein which accounts for 15%-20% of all breast cancer cases. TNBC is considered to be a poorer prognosis than other types of breast cancer, mainly because it involves more aggressive phenotypes that are similar to stem cell-like cancer cells (cancer stem cell, CSC). Thus, targeted treatment of TNBC remains a major challenge in clinical practice. This review article surveys the latest evidence concerning the role of genomic alteration in current TNBC treatment responses, current clinical trials and potential targeting sites, CSC and drug resistance, and potential strategies targeting CSCs in TNBC. Furthermore, the role of insulin-like growth factor 1 receptor (IGF-1R) and nicotinic acetylcholine receptors (nAChR) in stemness expression, chemoresistance, and metastasis in TNBC and their relevance to potential treatments are also discussed and highlighted.

AB - Triple-negative breast cancer (TNBC) is cancer that tested as negative for estrogen receptors (ER), progesterone receptors (PR), and excess human epidermal growth factor receptor 2 (HER2) protein which accounts for 15%-20% of all breast cancer cases. TNBC is considered to be a poorer prognosis than other types of breast cancer, mainly because it involves more aggressive phenotypes that are similar to stem cell-like cancer cells (cancer stem cell, CSC). Thus, targeted treatment of TNBC remains a major challenge in clinical practice. This review article surveys the latest evidence concerning the role of genomic alteration in current TNBC treatment responses, current clinical trials and potential targeting sites, CSC and drug resistance, and potential strategies targeting CSCs in TNBC. Furthermore, the role of insulin-like growth factor 1 receptor (IGF-1R) and nicotinic acetylcholine receptors (nAChR) in stemness expression, chemoresistance, and metastasis in TNBC and their relevance to potential treatments are also discussed and highlighted.

KW - Cancer stem cell

KW - IGF-1R

KW - NACHR

KW - Recurrence

KW - Resistance

KW - TNBC

UR - http://www.scopus.com/inward/record.url?scp=85073342106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073342106&partnerID=8YFLogxK

U2 - 10.3390/cancers11091334

DO - 10.3390/cancers11091334

M3 - Review article

AN - SCOPUS:85073342106

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 9

M1 - 1334

ER -